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Abstract   
 
Background:  Intracerebral hemorrhage is a devastating event that may occur 
spontaneously or as the result of a trauma. Anticoagulation-related hemorrhages are 
increasing with the growing number of patients on oral anticoagulation therapy.  Off label 
use of recombinant activated factor VIIa (rFVIIa) is effective in lowering the INR, thus 
rapidly decreasing the risk of hematoma expansion and allowing for faster response when 
emergent surgery is indicated. rFVIIa, currently approved by the FDA for use in 
hemophiliac patients only, has been demonstrated to quickly reverse the effects of 
anticoagulation therapy, with the additional benefit of reducing further hematoma growth. 
However, it’s not without complications. rFVIIa has been reported as increasing the 
occurrence of post treatment thromboembolic events. This review will assess published 
studies that have evaluated the safety of rFVIIa in non-hemophiliac patients presenting 
with acute spontaneous intracerebral hemorrhages 
Methods:  A systematic review of the past 6 years of English-language published 
literature was conducted using MEDLINE, CINAHL, and a multi-resource EBM 
database using keywords rFVIIa, thromboembolic events, intracerebral hemorrhage and 
subordinate headings. Articles that examined safety with the use of rFVIIa in non 
hemophiliac patients to manage spontaneous intracerebral hemorrhages were selected. 
Five studies were analyzed for quality and noteworthy results. 
 
Results:  These studies have demonstrated that the risk of thromboembolic events at low 
doses, <80 µg/kg of rFVIIa, is comparable to that of a placebo. Simultaneously, they 
have demonstrated that with higher doses, ≥ 80 µg/kg of rFVIIa, in high-risk patients, 
occurrence of thromboembolic events increases substantially.  
 
Conclusion:  These findings suggest that it would be appropriate at this time to pursue 
further investigations comparing the safety and efficacy of rFVIIa with that of Vitamin K 
and FFP in well-designed, randomized controlled trials in addition to studies that include 
patients on oral anticoagulant therapy.  
 
Keywords: rFVIIa, thromboembolic events, arterial/venous thromboembolism, 
spontaneous intracerebral hemorrhage, 
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The Risk of Thromboembolic Events in the Use of Recombinant 
Activated Factor VII to Control Bleeding in Nonhemophiliac Patients 
With Spontaneous Intracerebral Hemorrhages: A Systematic Review 
 
 BACKGROUND 
  
 Intracerebral hemorrhage (ICH) is the deadliest, most disabling and least treatable 
form of stroke. Approximately 40 percent of patients die within one month of ICH onset 
and 66% of those who do survive never regain functional independence.1  Patients on oral 
anticoagulation therapy are at an increased risk for ICH.2  However, prompt treatment 
can prevent acute bleeds from becoming chronic disabilities that, in turn, negatively 
affect functional independence. 2-7  When an ICH occurs in patients who use an 
anticoagulation therapy, the prompt reversal of the elevated international normalized ratio 
(INR), as well as an effective therapy, is required to stop bleeding and prevent hematoma 
expansion.  Additionally, when surgical intervention is mandated, fast reversal of 
anticoagulation   therapy becomes vital for patient survival and positive clinical 
outcomes. 8-11   
 Current practice includes the utilization of vitamin K and/or fresh frozen plasma 
(FFP) to reverse anticoagulation.11 Unfortunately, these agents are slow-acting and 
potentially risky, as patients may suffer from allergic or transfusion reactions.12  With so 
many ICH patients presenting with a history of cardiovascular disease, the additional 
volume of FFP could result in congestive heart failure, volume overload, or lung 
damage.6, 11, 13 An added concern to the use of FFP lies in the fact that while it is has been 
demonstrated to be effective in reversing the INR; it does not control the growth of the 
hematoma and is thus not an effective therapy.13  
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 Conversely, recombinant activated Factor VIIa (rFVIIa), currently approved  by 
the FDA for use in hemophiliac patients only, has been demonstrated to quickly reverse 
the effects of anticoagulation therapy, with the additional benefit of  reducing further 
hematoma growth.14, 15 Its use has demonstrated better clinical outcomes, allowed for 
more rapid surgical response,11 and has proven to be more cost effective16 than vitamin K 
or fresh frozen plasma alone or in combination. It is not, however, without potential risks, 
as a small series of studies performed on the effectiveness of rFVIIa has also revealed an 
increased risk of thromboembolic events secondary to the hemostatic nature of the 
agent.14, 15, 17, 18 
 This review will assess published studies that have evaluated the safety of rFVIIa 
in non-hemophiliac patients presenting with acute spontaneous intracerebral 
hemorrhages. 
 
METHODS 
 A search of the literature was performed using Medline, CINAHL, and a multi- 
resource EBM database. Search terms included: recombinant proteins, rFVIIa, 
thromboembolic events, blood coagulation, thrombosis, complications, intracerebral 
hemorrhage, arterial/venous thromboembolism, safety, adverse events, toxicity and 
warfarin.   
 Included in this review are cohort studies and randomized placebo-controlled 
studies that evaluated the safety of rFVIIa in non-hemophiliac patients with spontaneous 
intracerebral bleeding.  Studies were limited to those published from 2004-2010 in 
English text.   
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 The search term and study results were then compiled and analyzed.  Studies that 
did not fit the criteria were considered for the background and discussion portion of this 
review. 
 
RESULTS 
 
 A total of five studies were published between 2004 and 2010 that met the criteria 
for assessing the risk of thromboembolic events in spontaneous intracerebral hemorrhage 
(sICH) patients receiving rFVIIa therapy. (Table 1) These articles addressed the questions 
relating to the number of thromboembolic events (TEs), the risk factors and the dosing 
impacts of rFVIIa in comparison to placebo. The number of arterial TEs and the number 
of venous TEs were noted in all studies as were serious adverse events (SAEs) i.e., MIs 
and cerebral infarctions. The sample sizes ranged from 48 to 841 with all studies being 
randomized controlled trials.   
 The Diringer et al studies14, 19 have been in the foreground for research on this 
topic, presenting two separate trials; one in 200814 and one in 2010 (FAST Trial).19 The 
2008 study, involving 486 patients, randomized patients into investigation groups 
including a placebo group, patients who received a single dose of 5 µg/kg – 80 µg/kg 
rFVIIa , and patients who received a single dose of 120 µg/kg-160 µg/kg rFVIIa.  This 
study excluded high-risk patients with any history of thromboembolic events.14  
 The study concluded that there was no overall increase in occurrence of total TEs 
in rFVIIa-treated patients; however, there were more arterial TEs in the high dose group 
(120 to 160 µg/kg) compared with placebo (5.4% versus 1.7%; P=0.13).14  
SAEs recorded were specific to arterial events. Myocardial ischemia (n=9) and 
ischemic stroke (n=9) occurred in 5.4% of the population receiving rFVIIa vs. 1.7% of 
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the population receiving placebo. (P=0.13) A regression analysis identified high doses 
(120 to 160 µg/kg) of rFVIIa as the only factor associated with arterial TEs (OR=6.75; 
P=0.02).14 
 Another Diringer et al study was The FAST Trial (Factor Seven for Acute 
Hemorrhagic Stroke of 2010).19 It was a multicenter, randomized, placebo-controlled trial 
that placed 841 patients presenting within 3 hours of sICH into groups receiving either 20 
µg/kg of rFVIIa, 80 µg/kg of rFVIIa, or placebo to define the risk factors and frequency 
of thromboembolic events when treating sICH with rFVIIa. Patients were excluded from 
the FAST Trial if they had a glascow score <5, planned surgery, had received oral 
anticoagulants, suffered from sepsis, crush injury, pre-existing disability, were pregnant 
or had a history of TEs within the last 30 days. Risk factors identified by the study 
included: 
a)    age >65 years, (OR 1.14/5years; 95% CI 1.03-1.27; P=0.012),  
b)   prior use of antiplatelet agents, (OR = 1.83; 95% CI 1.04-3.20; P= 0.035),  
c)   signs of cardiac or cerebral ischemia at presentation, (OR= 4.19; 95% CI 1.46-
10.54; P= 0.010), and 
d)    receiving 80 µg/kg rFVIIa (OR= 2.14; 95% CI 1.09-4.41; P= 0.031).  
 A total of 225 events were noted: 78 arterial and 47 venous. Venous events were 
similar across all groups: 17 (6%) placebo, 15 (5%) in 20 µg/kg rFVIIa, and 15 (5%) in 
80 µg/kg rFVIIa (P=0.45). The arterial events revealed a marked difference between the 
placebo and 20 µg/kg groups, as compared to the 80 µg/kg group.  In the placebo group, 
49 (27%) arterial events occurred, with 47 (26%) in the 20µg/kg group, and 82 (46%) in 
the 80 µg/kg group (P=0.04).19   
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Two events were defined within arterial TEs as serious adverse events (SAE): 
MIs and cerebral infarcts. In the placebo group, 41 (15%) MIs occurred, while the 20 
µg/kg group reported 36 (13%) and the 80 µg/kg group reported 64 (22%) (P=0.04). In 
contrast, cerebral infarctions, possibly related to the study drug, occurred in 7, 5, and 8 
patients in the placebo, 20 µg/kg, and 80 µg/kg groups, respectively.19 
  The FAST Trial concluded that higher doses of rFVIIa administered in a high-risk 
population are, in fact, associated with a slight increased risk of what were typically 
minor cardiac events. They also concluded that this increased risk may be outweighed by 
the proven effectiveness of rFVIIa in slowing bleeding.19  
 Mayer et al conducted three separate studies: Mayer et al January 2005,18 Mayer 
et al February 200515 and Mayer et al 2008.17 His later two trials were held in conjunction 
with the Diringer et al14 trial of 2008 and the FAST trial19 published in 2010.   
 In Mayer et al18 January 2005, a 48-patient randomized controlled, dose 
escalation trial found no difference in the occurrence of TEs when comparing all dosing 
groups with the placebo-controlled group.18 
 They listed 6 reported adverse events that were possibly related to rFVIIa but 
these were limited to rash, headache, vomiting, fever, ECG T-wave inversion, and 2 cases 
of DVT. Ten patients reported 12 SAEs including neurological deterioration (n=6), 
unstable angina, pneumonia, urosepsis, dyspnea, av-malformation (n=1 each) and DVT 
(n=2). The study states that no cases of myocardial ischemia or consumption 
coagulopathy were found.18  
 In the Mayer et al15 study of February 2005, 399 patients presenting within <3 
hours post sICH were randomized into rFVIIa dosage levels of  40 µg/kg, 80 µg/kg,  160 
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µg/kg and a placebo group. It was found that arterial adverse events in all patient groups 
receiving rFVIIa were increased 5% vs. 0% increase in the placebo control (p= 0.01), and 
an increased number of total serious adverse events, mainly myocardial or cerebral 
infarctions, in all patient groups receiving rFVIIa over those receiving placebo: 7% vs. 
2% (P= 0.12).15 Mayer also noted, however, that there appeared to be an improvement in 
neurological outcomes that had not been reported in other studies.15 
 In the most recent Mayer et al17 trial (2008), 841 patients were followed. Patients 
were excluded if the ICH was secondary to trauma, if there was a known cause of the 
ICH, if the patients were taking oral anticoagulants, had a history of a thromboembolic 
event, any coagulopathy disorder, sepsis, or pregnancy. Clinical outcomes were as 
follows: 21(8%) arterial TEs occurred in the placebo group, 24 (9%) arterial TEs in the 
20 µg/kg group, and 31 (10%) arterial TEs occurred in the 80 µg/kg group. Myocardial 
infarctions occurred in 8 (3%) of the placebo group, 11 (4%) of the 20 µg/kg group, with 
25 (8%) occurring in the 80 µg/kg group. The percentage of patients suffering cerebral 
infarctions were 1%, 1% and 4% of patients in the placebo, 20 µg/kg and 80 µg/kg 
groups respectively. The occurrence of venous events was similar in all groups. (Table 1) 
Results of the trial demonstrated that arterial thromboembolic events were more frequent 
in the group receiving the 80 µg/kg dose vs. the placebo group (9% vs. 4% P=0.04).17     
 
DISCUSSION 
 Intracerebral hemorrhage is a devastating event that may occur spontaneously or 
as the result of a trauma. Anticoagulation-related hemorrhages are increasing with the 
growing number of patients on oral anticoagulation  therapy.2  The use of rFVIIa is 
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effective in lowering the INR, thus rapidly decreasing the risk of hematoma expansion 
and allowing for faster response when emergent surgery is indicated. It has also shown to 
help in minimizing the likelihood of a poor long-term outcome.2, 5, 13 
 However, the currently available published studies are incomplete in several 
respects. Many questions are left unanswered and concerns have not been addressed 
about the wisdom of assuming that rFVIIa usage is devoid of negative potential risks. In 
the studies that have been  reviewed, only the FAST trial19 included patients that had a 
thromboembolic event greater than 30 days prior to onset of sICH symptoms and none of 
them included patients who were currently receiving anticoagulation therapy.19  While on 
the face each study appears to be reporting about different population groups, the patient 
numbers in the groups are quite similar. This raises questions as to whether or not they 
were actually studying the same patient populations.  Admittedly, the patient acceptance 
criteria was slightly different, but the total patient numbers are uncomfortably similar as 
were the overall results.  
 The available studies have other significant limitations or factors that should be 
addressed.  All studies were performed by the same group of investigators over a period 
of six years. Each of the authors either was employed by, consulted for, or had received 
funds from Novo-Nordisc, the manufacturer of the rFVIIa product being used. While not 
meant to disparage either the investigators or their results, there are no randomized 
controlled trials, specifically for sICH, conducted by completely independent 
investigative teams. 
Earlier studies eliminated high-risk patients which may have skewed  practical 
application. 14, 15, 17, 18  The only study that kept higher-risk patients eligible was the 
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FAST trial.19 The FAST trial exclusion criteria were identical to that of the previous 
studies, however, they excluded patients with a thromboembolic event only if said event 
had occurred within 30 days prior to the ICH.19  Furthermore, later studies were 
composite studies of early ones with slight changes to inclusion and exclusion protocols. 
The Mayer et al17 2008 study was conducted specifically to be included in the FAST trial. 
However, high-risk patients were eliminated from their trial, with the possible net effect 
that the results appear more promising than they would be in reality. 
No trial reviewed included patients that would appear to be the most at risk for 
sICH, namely those who are taking oral anticoagulants.2, 5, 12, 20 One study, the Robinson 
study,11 did include patients taking oral anticoagulants. It was not included in this review 
because it was a retrospective cohort study that did not have a well-defined control group. 
However, Robinson’s trial found  that  rFVIIa carried a slightly higher risk of 
thromboembolic complications, though most were minor DVTs without embolism. 11  
The study concluded that the risk of thromboembolic events was not higher in 
anticoagulated populations than in populations reported in the FAST trial, suggesting that 
it would be safe to compare rFVIIa with FFP in a randomized controlled trial.11   
Perhaps one of the most significant challenges with each of the studies is that of 
the placebo group. Each study compared the rFVIIa results to placebo results while not 
specifying whether placebo was no treatment or whether it was current protocol of 
Vitamin K and/or fresh frozen plasma (FFP) making them difficult to replicate.  No study 
reviewed overtly compared the three protocol approaches. 
 On a positive note, the usage of rFVIIa does appear to offer an overall positive 
protocol choice for the treatment of ICEs, even with the noted adverse events. For 
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example, the FAST trial19 demonstrated  more adverse events related to higher doses in 
higher-risk populations than  the other four trials reported. An increase in thrombotic 
events was also reported, specifically a relative increase in myocardial events in those 
receiving rFVIIa.19 
 Surprisingly, the incidence of venous thromboembolic events was consistent 
among comparison groups in all studies,14, 15, 17-19  raising the question of what 
specifically is occurring physiologically to focus events arterially. It has been considered 
that age and antiplatelet therapy use were associated with the increased risk of arterial 
events. These patient populations are more likely to have ulcerated or ruptured 
atheromatous plaques resulting thromboses.7 Still, the overall risk appears to be relatively 
small when compared to the effectiveness at slowing bleeding.19  
 Even accounting for potential flaws, the aforementioned studies have established 
that there is a slight risk of a thromboembolic event, especially at higher doses of rFVIIa 
or when risk factor are present, as compared to an unnamed placebo.  Extensive and long-
term studies that compare rFVIIa usage to current practices, such as the use of Vitamin K 
and FFP, need to be conducted, both in general and high-risk patient populations.  
 
CONCLUSION 
 
 The use of recombinant factor VIIa, although currently approved by the FDA for 
use in hemophiliac patients only, reverses the effects of oral anitcoagulants more 
expeditiously, allows for rapid surgical response,8-10  demonstrates better clinical 
outcomes,2-6, 11, 21  and is more cost effective when compared to placebo, vitamin K and 
FFP.16  Questions of safety, specifically the perceived increased risk of thromboembolic 
events, have also been the topic of many studies over the last six years.  
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 These studies have demonstrated that the risk of thromboembolic events at low 
doses of rFVIIa is comparable to that of a placebo.14, 15, 17, 19   
Simultaneously, these studies have also demonstrated that at higher doses, the risk of 
thromboembolic events increases substantially.19  
 In total, these findings suggest that it would be appropriate at this time to pursue 
further investigations comparing the safety and efficacy of rFVIIa with that of Vitamin K 
and FFP in well-designed, randomized controlled trials in addition to studies that include 
patients on oral anticoagulant therapy.  
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 TABLE 1 
 
Author/  Title/ 
Journal/Year 
Patients/ 
Population 
Intervention 
and Comparison 
Adverse Events Study Type Validity/Jadad 
Score 
Comments 
Diringer M. et al, 
Thromboembolic Events 
with Recombinant 
Activated Factor VII in 
Spontaneous Intracerebral 
Hemorrhage, Stroke, 2010 
841 Pts presenting 
within <3 hours post 
spontaneous 
intracerebral 
hemorrhage 
20 or 80 µg/kg 
rFVIIa vs. 
placebo 
47 arterial TEs w/20 
µg/kg 
82 arterial TEs w/ 80 
µg/kg 
49 arterial TEs 
w/placebo 
Venous events were 
similar in all groups 
FAST/RCT 5 Authors either received 
consulting fees or were 
employees of  Novo 
Nordisk 
Mayer S. et al Efficacy 
and Safety of Recombinant 
Activated Factor VII for 
Acute Intracerebral 
Hemorrhage 
841 Pts presenting 
within <4 hours post 
spontaneous 
intracerebral 
hemorrhage 
20 or 80 µg/kg 
rFVIIa vs. 
placebo 
21arterial TEs w/placebo 
24 arterial TEs w/20 
µg/kg 
31 arterial TEs w/ 80 
µg/kg 
Venous events were 
similar in all groups 
RCT 4 Authors either received 
consulting fees or were 
employees of  Novo 
Nordisk 
 
Diringer M. et al, Risk of 
Thromboembolic Events in 
Controlled Trials of rFVIIa 
in Spontaneous 
Intracerebral Hemorrhage, 
Stroke, 2008 
 
486  pts presenting 
within <3 hours post 
spontaneous 
intracerebral 
hemorrhage 
 
Single dose 
rFVIIa (5-160 
µg/kg) vs. 
placebo 
 
4 arterial TEs w/5-40 
µg/kg 
3 arterial TEs w/ 80 
µg/kg 
10 arterial TEs w/>120 
µg/kg 
2 arterial TEs w/ placebo 
Venous events similar in 
all groups 
 
RCT 
 
5 
 
Authors either received 
consulting fees or were 
employees of  Novo 
Nordisk 
 
       
Mayer S. et al, 
Recombinant Activated 
Factor VII for Acute 
Intracerebral Hemorrhage, 
New England Journal of 
Medicine, 2005 
399 Pts 
presenting 
within <3 hours 
post spontaneous 
intracerebral 
hemorrhage 
40 vs. 80 vs. 160 
µg/kg   rFVIIa vs. 
placebo 
16 arterial TEs w/ 
rFVIIa 
0 arterial events in 
placebo 
RCT 4 Improved neurological 
outcomes in patients 
receiving rFVIIa. 
Authors received 
compensation for Novo 
Nordisk 
 
Mayer S. et al, Safety and 
Feasibility of Recombinant 
Factor VIIa for Acute 
Intracerebral Hemorrhage, 
Stroke, 2005 
48 Pts presenting 
within <3 hours 
post spontaneous 
intracerebral 
hemorrhage. 
10, 20, 40, 80, 120, 
and 160  µg/kg   
rFVIIa vs. placebo 
No difference noted in 
SAE or TE  
Dose 
Escalation, 
RCT, dbl 
blinded trial 
5 No neurological change 
demonstrated in pts, 
study population too 
small to be effective. 
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